New Delhi, Sep 5 (SocialNews.XYZ) Cohance Lifescience on Saturday said it has received a US Food and Drug Administration (USFDA) Form 483 containing four observations following an inspection of its formulation facility in Shamshabad, Telangana. In an exchange filing, the company said the USFDA inspection was conducted from August 27 to September 4, 2026, at its finished dosage form (FDF) manufacturing plant. The inspection concluded with the issuance of a Form FDA 483 with four observations. Cohance Lifescience said it has initiated appropriate corrective and preventive actions (CAPA) and will submit its response to the US regulator within the stipulated timeline.